tetano
Editor, Senior Moderator
Sci Adv
. 2023 Oct 6;9(40):eadh0761.
doi: 10.1126/sciadv.adh0761. Epub 2023 Oct 4. History of primary-series and booster vaccination and protection against Omicron reinfection
Hiam Chemaitelly[SUP] 1 2 3 [/SUP], Houssein H Ayoub[SUP] 4 [/SUP], Patrick Tang[SUP] 5 [/SUP], Peter V Coyle[SUP] 6 7 8 [/SUP], Hadi M Yassine[SUP] 7 9 [/SUP], Asmaa A Al Thani[SUP] 7 9 [/SUP], Hebah A Al-Khatib[SUP] 7 9 [/SUP], Mohammad R Hasan[SUP] 5 [/SUP], Zaina Al-Kanaani[SUP] 6 [/SUP], Einas Al-Kuwari[SUP] 6 [/SUP], Andrew Jeremijenko[SUP] 6 [/SUP], Anvar Hassan Kaleeckal[SUP] 6 [/SUP], Ali Nizar Latif[SUP] 6 [/SUP], Riyazuddin Mohammad Shaik[SUP] 6 [/SUP], Hanan F Abdul-Rahim[SUP] 10 [/SUP], Gheyath K Nasrallah[SUP] 7 9 [/SUP], Mohamed Ghaith Al-Kuwari[SUP] 11 [/SUP], Adeel A Butt[SUP] 3 6 12 [/SUP], Hamad Eid Al-Romaihi[SUP] 13 [/SUP], Mohamed H Al-Thani[SUP] 13 [/SUP], Abdullatif Al-Khal[SUP] 6 [/SUP], Roberto Bertollini[SUP] 13 [/SUP], Laith J Abu-Raddad[SUP] 1 2 3 10 14 [/SUP]
Affiliations
Laboratory evidence suggests a possibility of immune imprinting for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We investigated the differences in the incidence of SARS-CoV-2 reinfection in a cohort of persons who had a primary Omicron infection, but different vaccination histories using matched, national, retrospective, cohort studies. Adjusted hazard ratio for reinfection incidence, factoring adjustment for differences in testing rate, was 0.43 [95% confidence interval (CI): 0.39 to 0.49] comparing history of two-dose vaccination to no vaccination, 1.47 (95% CI: 1.23 to 1.76) comparing history of three-dose vaccination to two-dose vaccination, and 0.57 (95% CI: 0.48 to 0.68) comparing history of three-dose vaccination to no vaccination. Divergence in cumulative incidence curves increased markedly when the incidence was dominated by BA.4/BA.5 and BA.2.75* Omicron subvariants. The history of primary-series vaccination enhanced immune protection against Omicron reinfection, but history of booster vaccination compromised protection against Omicron reinfection. These findings do not undermine the public health utility of booster vaccination.
. 2023 Oct 6;9(40):eadh0761.
doi: 10.1126/sciadv.adh0761. Epub 2023 Oct 4. History of primary-series and booster vaccination and protection against Omicron reinfection
Hiam Chemaitelly[SUP] 1 2 3 [/SUP], Houssein H Ayoub[SUP] 4 [/SUP], Patrick Tang[SUP] 5 [/SUP], Peter V Coyle[SUP] 6 7 8 [/SUP], Hadi M Yassine[SUP] 7 9 [/SUP], Asmaa A Al Thani[SUP] 7 9 [/SUP], Hebah A Al-Khatib[SUP] 7 9 [/SUP], Mohammad R Hasan[SUP] 5 [/SUP], Zaina Al-Kanaani[SUP] 6 [/SUP], Einas Al-Kuwari[SUP] 6 [/SUP], Andrew Jeremijenko[SUP] 6 [/SUP], Anvar Hassan Kaleeckal[SUP] 6 [/SUP], Ali Nizar Latif[SUP] 6 [/SUP], Riyazuddin Mohammad Shaik[SUP] 6 [/SUP], Hanan F Abdul-Rahim[SUP] 10 [/SUP], Gheyath K Nasrallah[SUP] 7 9 [/SUP], Mohamed Ghaith Al-Kuwari[SUP] 11 [/SUP], Adeel A Butt[SUP] 3 6 12 [/SUP], Hamad Eid Al-Romaihi[SUP] 13 [/SUP], Mohamed H Al-Thani[SUP] 13 [/SUP], Abdullatif Al-Khal[SUP] 6 [/SUP], Roberto Bertollini[SUP] 13 [/SUP], Laith J Abu-Raddad[SUP] 1 2 3 10 14 [/SUP]
Affiliations
- PMID: 37792951
- DOI: 10.1126/sciadv.adh0761
Laboratory evidence suggests a possibility of immune imprinting for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We investigated the differences in the incidence of SARS-CoV-2 reinfection in a cohort of persons who had a primary Omicron infection, but different vaccination histories using matched, national, retrospective, cohort studies. Adjusted hazard ratio for reinfection incidence, factoring adjustment for differences in testing rate, was 0.43 [95% confidence interval (CI): 0.39 to 0.49] comparing history of two-dose vaccination to no vaccination, 1.47 (95% CI: 1.23 to 1.76) comparing history of three-dose vaccination to two-dose vaccination, and 0.57 (95% CI: 0.48 to 0.68) comparing history of three-dose vaccination to no vaccination. Divergence in cumulative incidence curves increased markedly when the incidence was dominated by BA.4/BA.5 and BA.2.75* Omicron subvariants. The history of primary-series vaccination enhanced immune protection against Omicron reinfection, but history of booster vaccination compromised protection against Omicron reinfection. These findings do not undermine the public health utility of booster vaccination.